Etanercept therapy for psoriatic arthritis in the presence of recurrent nonyhodgkin lymphoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent nonYHodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of nonYHodgkin lymphoma.However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)301-303
Number of pages3
JournalJournal of Clinical Rheumatology
Volume18
Issue number6
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Psoriatic Arthritis
Lymphoma
Tumor Necrosis Factor-alpha
Therapeutics
Recurrence
Psoriasis
Adenocarcinoma
Etanercept

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

@article{4fa3befee34b47a0bbfb17cdb109ef29,
title = "Etanercept therapy for psoriatic arthritis in the presence of recurrent nonyhodgkin lymphoma",
abstract = "Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent nonYHodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of nonYHodgkin lymphoma.However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.",
author = "Sneha Pai and Elliot Rosenstein and Neil Kramer",
year = "2012",
month = "9",
day = "1",
doi = "10.1097/RHU.0b013e3182685515",
language = "English (US)",
volume = "18",
pages = "301--303",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Etanercept therapy for psoriatic arthritis in the presence of recurrent nonyhodgkin lymphoma. / Pai, Sneha; Rosenstein, Elliot; Kramer, Neil.

In: Journal of Clinical Rheumatology, Vol. 18, No. 6, 01.09.2012, p. 301-303.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Etanercept therapy for psoriatic arthritis in the presence of recurrent nonyhodgkin lymphoma

AU - Pai, Sneha

AU - Rosenstein, Elliot

AU - Kramer, Neil

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent nonYHodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of nonYHodgkin lymphoma.However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.

AB - Tumor necrosis factor inhibitors (TNFi) have established efficacy in psoriasis and psoriatic arthritis; however, there are concerns regarding the risk of lymphoma with their use. Although current data suggest that this risk is not increased with TNFi treatment, there are no data on the risk of recurrence of previously treated lymphoma under TNFi therapy. Herein, we describe a 46-year-old man with recurrent nonYHodgkin lymphoma whose refractory psoriatic arthritis was effectively treated for 5.5 years with the TNFi etanercept, initiated just 7 months after achieving lymphoma remission, without recurrence of nonYHodgkin lymphoma.However, he subsequently died 6.5 years later of pancreatic adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84868235841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868235841&partnerID=8YFLogxK

U2 - 10.1097/RHU.0b013e3182685515

DO - 10.1097/RHU.0b013e3182685515

M3 - Article

VL - 18

SP - 301

EP - 303

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 6

ER -